Delivery Order SPE2DB22D2206-SPE2DB25FJB84
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,181.16 to AmerisourceBergen Drug Corp for Ofev 150 mg capsules (60-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026. The place of performance...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ofev 150 mg capsules (60-count units) with a ceiling value of $8,590.58. This is a firm fixed price delivery order with an ultimate completion date of September 3, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ofev (nintedanib) 150 mg capsules in quantities of 60 units. This is a firm fixed-price delivery order with a ceiling value of $8,590.58 and an ultimate completion date of August 8, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ofev 150 mg capsules (60-count units). This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The contract is set to be completed by September 8, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ofev 100 mg capsules (60-count units) with a ceiling value of $17,260.58. This firm fixed-price delivery order, which is expected to be completed by September 2, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ofev (nintedanib) is a medication...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for the supply of Ofev 150 mg capsules (60-count) on July 22, 2025, with completion scheduled for August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ofev 150 mg capsules (60-unit packages) with a ceiling value of $8,590.58. This firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing contract vehicle...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,590.58 on August 19, 2025, for the supply of Ofev 150 mg capsules (60-count). This is a firm fixed price delivery order with a completion date of September 10, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of OFEV 100 mg capsules (60-count units) valued at $8,630.28. This is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ofev (nintedanib) 100 mg capsules in a quantity of 60 units, with a ceiling value of $8,630.28. This is a firm fixed price delivery order with an ultimate completion date of September 10, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJB84Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for 60 capsules of Ofev 150 mg on July 25, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be performed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a typical transaction under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Ofev (nintedanib) is a specialty pharmaceutical used for treating certain lung conditions, demonstrating the contractor's role in providing specialized medications to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 7/25/25 |